Reported Earlier, MediciNova Announces Two Abstracts Regarding MN-001 And MN-002 Accepted For Presentation At The 92nd EAS 2024 Congress
Reported Earlier, MediciNova Announces Two Abstracts Regarding MN-001 And MN-002 Accepted For Presentation At The 92nd EAS 2024 Congress
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that two abstracts entitled "STUDY PROTOCOL TO EVALUATE MN-001'S (TIPELUKAST) EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), HYPERTRIGLYCERIDEMIA (HTG) AND TYPE-2 DIABETES MELLITUS (T2DM)" and "MN-002, THE METABOLITE OF MN-001(TIPELUKAST) PROMOTES MACROPHAGE CHOLESTEROL EFFLUX" have been accepted and selected for poster presentation at the 92nd European Atherosclerosis Society (EAS) 2024 Congress to be held May 26-29, 2024.
在纳斯达克全球市场（纳斯达克股票代码：MNOV）和东京证券交易所标准市场（代码编号：4875）上市的生物制药公司MedicinOVA, Inc. 今天宣布，两份题为 “评估 MN-001（TIPELUKAST）对非酒精性脂肪肝病（NAFLD）、高甘油三酯血症（HTG）和 TYPE-2 受试者的疗效、安全性和耐受性的研究协议” 的摘要 “糖尿病（T2DM）” 和 “MN-002，MN-001（TIPELUKAST）的代谢物，促进巨噬细胞胆固醇外流” 已被接受并入选海报展出第92届欧洲动脉粥样硬化学会（EAS）2024年大会将于2024年5月26日至29日举行。